What is Mana.bio?
Headquartered in Tel Aviv, Israel, Mana.bio operates at the intersection of computational biology and pharmaceutical innovation. The company specializes in an AI-driven platform that discovers and optimizes novel, customizable lipid nanoparticles (LNPs). By focusing on tissue-specific delivery, Mana.bio addresses one of the most significant bottlenecks in modern medicine: the precise and efficient transport of genetic payloads to target cells. This technological capability positions the firm as a critical player in the evolving landscape of mRNA and gene therapy, providing a scalable solution for next-generation medical interventions.
How much funding has Mana.bio raised?
Mana.bio has raised a total of $19.5M across 1 funding round:
Angel/Seed
$19.5M
Angel/Seed (2023): $19.5M with participation from Andreessen Horowitz, The NFX, and LionBird
Key Investors in Mana.bio
Andreessen Horowitz
A prominent venture capital firm based in Menlo Park, California, known for its extensive portfolio in both early-stage startups and established growth-stage technology companies.
The NFX
A venture capital firm specializing in pre-seed and seed-stage investments, with a particular focus on network-effect businesses and transformative technologies across global markets.
LionBird
A health-tech focused venture firm that provides pre-scale capital to startups aiming to disrupt the healthcare industry through innovative technological solutions.
What's next for Mana.bio?
Following this major strategic investment, Mana.bio is expected to scale its operational capacity and expand its pipeline of therapeutic candidates. The infusion of capital will likely be directed toward enhancing the predictive accuracy of its AI models and broadening the scope of its LNP library. As the company transitions from its initial development phase toward more robust clinical validation, the focus will remain on establishing strategic partnerships with global pharmaceutical entities. By leveraging its unique delivery platform, Mana.bio aims to set a new standard for efficacy and safety in the administration of nucleic acid-based treatments, ultimately aiming to unlock new therapeutic modalities for previously untreatable conditions.
See full Mana.bio company page
